查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1929532

生物可降解冠状动脉支架市场：按材料、应用、最终用户和分销管道划分，全球预测（2026-2032年）

Biodegradable Coronary Stents Market by Material, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，可生物降解冠状动脉支架市场价值将达到 14.1 亿美元，到 2026 年将成长至 15.2 亿美元，到 2032 年将达到 22.4 亿美元，复合年增长率为 6.79%。

主要市场统计数据
基准年 2025 14.1亿美元
预计年份：2026年 15.2亿美元
预测年份：2032年 22.4亿美元
复合年增长率 (%) 6.79%

在新的临床需求和技术成熟的推动下，可生物降解的冠状动脉支架正在彻底改变以患者为中心的血管治疗和手术效率。

可生物降解冠状动脉支架代表了介入性心臟病学的一个转折点，它将材料科学的进步与血管修復和长期血管完整性方面不断变化的临床需求相结合。目前的讨论重点在于可吸收装置能否在减少与永久性金属支架相关的长期併发症的同时，实现二次介入治疗和生理性血管反应。临床医生和医疗机构越来越关注即时手术疗效和长期血管护理之间的权衡，这促使器械研发人员不断改进支架梁设计、药物释放型曲线和吸收动力学。

材料创新、监管政策明朗化和以价值为导向的医疗保健模式等因素的汇聚，正在加速可生物降解支架的结构性变革。

由于技术、监管和商业性因素的共同作用，可生物降解冠状动脉支架的市场格局正在经历变革性变化。材料创新正从早期的聚合物概念发展到可吸收金属和混合结构，力求在径向强度和可预测的降解性之间取得平衡。这些技术改进，加上药物释放型涂层和递送系统的迭代优化，正在增强临床医生的信心，并扩大可吸收支架的临床应用范围。

包括美国在 2025 年实施的关税变化累积转变，正在推动供应链重组、成本转移和战略采购应对措施。

2025年美国关税政策的实施，为可生物降解冠状动脉支架产业的企业带来了新的商业性复杂性，促使企业即时评估其采购、生产和库存策略。原料、成品医疗设备及相关组件的关税调整导致到岸成本上升和利润空间压缩，进而影响定价策略以及与医疗系统经销商的合约谈判。供应商和製造商正透过审查其采购基础、利用关税咨询服务以及探索透过贸易协定和关税分类来降低关税的潜在机制来应对这一挑战。

细分市场主导的竞争格局由材料选择、临床适应症、医疗环境和分销管道决定。

细分市场分析揭示了材料科学、临床适应症、临床环境和分销管道如何共同影响可吸收冠状动脉装置的普及趋势。材料差异化仍然至关重要：铁基结构提供不同的降解特性和机械性能，镁基支架在强度和吸收性之间实现了独特的平衡，而聚合物平台（进一步细分为PDLLA和PLLA化学结构）则展现出不同的操作特性和药物释放型相容性。这些材料选择直接影响手术流程、影像相容性和术后监测要求。

区域趋势：基础设施、监管和报销差异导緻美洲、欧洲、中东和非洲以及亚太地区的采用模式不同

区域趋势反映了医疗基础设施、法规结构和报销环境的差异，对可生物降解冠状动脉支架的推广应用有显着影响。在美洲，临床医生对介入性心臟病学技术的熟悉程度以及医院网路结构的完善促进了技术的快速转移，而支付方的审查和采购通讯协定则要求明确证明其临床和经济价值。在欧洲、中东和非洲，不同的监管体系和多样化的报销管道导致推广应用的时间呈现出不均衡的局面。领先的心臟中心往往是早期采用者，随着各国医疗体系和支付方调整其医疗政策，推广应用的普及程度也会逐渐提高。

製造商、合约合作伙伴和经销商的竞争格局和策略倡议会影响整个医疗保健生态系统中的技术应用和临床协作。

竞争格局日益取决于临床合作的深度、生产和分销网络的灵活性以及上市后证据项目的稳健性。领先的医疗设备开发商正与学术心臟中心进行直接的临床合作，以验证手术效果和长期血管预后，同时拓展契约製造伙伴关係，以确保产能和组件供应的稳定性。与分销商和综合医疗网络的策略联盟有助于产品在门诊手术中心和多医院系统中广泛应用。包括医师培训、手术指导和售后服务临床支援在内的专属服务模式，有助于加速产品在高流量医疗机构的推广应用。

在不断变化的法规环境和贸易环境中，产业领导者可采取切实可行的策略来增强韧性、加速临床应用并优化商业模式。

产业领导者应协调一系列策略行动，以增强可降解支架领域的韧性，加速产品推广应用，并赢得临床顾客购买倾向率。首先，应优先产生符合支付方和临床医生决策标准的临床证据，重点关注真实世界结果、安全性终点以及在急性冠状动脉症候群和稳定性心绞痛患者群体中的疗效比较。其次，应制定灵活的製造地和供应商多元化计划，以降低关税和贸易风险，同时保持成本竞争力和准时交付的可靠性。

为了确保分析的严谨性，我们采用了稳健的调查方法，该方法结合了关键临床相关人员的访谈、供应链映射和三角验证的二手资讯分析。

本分析采用多方法调查方法，旨在确保分析的严谨性和实用性。研究人员对介入性心臟病专家、采购人员、监管负责人和分销合作伙伴进行了初步的定性访谈，以获取有关临床表现、采购动机和营运障碍的第一手资讯。此外，研究人员还进行了供应链图谱分析，追踪组件采购、生产依赖关係和分销管道，以识别潜在的薄弱环节和改进机会。

一份权威的综合分析报告，重点阐述了将影响可生物降解冠状动脉支架应用和创新轨蹟的临床、商业和政策优先事项。

结论部分总结了核心发现，并重点阐述了其对可生物降解冠状动脉支架生态系统中相关人员的直接影响。材料技术和器械设计的进步、日益严格的监管要求以及不断演变的支付模式，共同凸显了真实世界临床数据和供应链韧性的重要性。 2025年的关税趋势增加了商业风险，需要采购、製造和销售部门协同应对。器械的普及推广不仅取决于其性能，还取决于製造商能否证明其供应的可预测性、上市后监测以及与临床优先事项的契合度。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章 美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 按材料分類的可生物降解冠状动脉支架市场

  • 铁
  • 镁
  • 聚合物
    • PDLLA
    • PLLA

9. 按应用分類的可生物降解冠状动脉支架市场

  • 急性冠状动脉症候群
  • 稳定性心绞痛

第十章 依最终用户分類的可生物降解冠状动脉支架市场

  • 门诊手术中心
    • 医院所属的门诊手术中心
    • 独立门诊手术中心
  • 医院
    • 心臟中心
    • 综合医院

第十一章 可生物降解冠状动脉支架市场（依通路划分）

  • 直接竞标
  • 第三方经销商

第十二章 各地区可生物降解冠状动脉支架市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 生物可降解冠状动脉支架市场（依类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国可生物降解冠状动脉支架市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国可生物降解冠状动脉支架市场

第十七章：中国可生物降解冠状动脉支架市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Amaran BIoTechnology Co., Ltd.
  • Amendia, Inc.
  • Arterial Remodeling Technologies, Inc.
  • Biomedical Structures, Inc.
  • BIoTronik SE & Co. KG
  • Boston Scientific Corporation
  • Cook Medical LLC
  • Cordis Corporation
  • Elixir Medical Corporation
  • Endologix, Inc.
  • HeartFlow, Inc.
  • Hengrui Medicine Co., Ltd.
  • Inflow Dynamics Corp.
  • Johnson & Johnson Services, Inc.
  • Lepu Medical Technology（Beijing）Co., Ltd.
  • Meril Life Sciences Pvt. Ltd.
  • OrbusNeich Medical Company
  • Reva Medical, Inc.
  • Shanghai MicroPort Medical（Group）Co., Ltd.
  • Sino Medical Sciences Technology Inc.
  • Svelte Medical Systems Ltd.
  • Terumo Corporation
  • Translumina GmbH
  • Xeltis AG
Product Code: MRR-0A38069517FD

The Biodegradable Coronary Stents Market was valued at USD 1.41 billion in 2025 and is projected to grow to USD 1.52 billion in 2026, with a CAGR of 6.79%, reaching USD 2.24 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.41 billion
Estimated Year [2026] USD 1.52 billion
Forecast Year [2032] USD 2.24 billion
CAGR (%) 6.79%

Emerging clinical imperatives and technological maturation reshaping biodegradable coronary stents toward patient-centric vascular healing and procedural efficiency

Biodegradable coronary stents represent an inflection point in interventional cardiology, combining advances in materials science with evolving clinical priorities for vascular restoration and long-term vessel integrity. The contemporary conversation centers on the capacity of resorbable devices to reduce late-stage complications associated with permanent metallic scaffolds while enabling secondary interventions and physiological vessel responses. Clinicians and hospital systems are increasingly weighing the trade-offs between immediate procedural efficacy and long-term vessel healing, prompting device developers to refine strut designs, drug-elution profiles, and resorption kinetics.

As regulatory pathways have become more defined for bioresorbable technologies, stakeholder attention is shifting toward clinical evidence that demonstrates durable outcomes across diverse patient cohorts and lesion types. Parallel improvements in imaging, lesion preparation techniques, and adjunctive pharmacotherapy are reinforcing the practicality of these devices in routine practice. Consequently, procurement and clinical leaders are seeking deeper insight into comparative performance, supply chain resilience, and the operational implications of adopting biodegradable stents within catheterization lab workflows. The following analysis synthesizes these dynamics to inform strategic planning across product development, commercialization, and clinical adoption programs.

Converging forces of materials innovation, regulatory clarity, and value-based care models accelerating structural shifts in the biodegradable stent landscape

The landscape for biodegradable coronary stents is undergoing transformative shifts driven by converging technological, regulatory, and commercial forces. Material innovation is advancing beyond early polymer concepts to include alternative resorbable metals and hybrid constructs that aim to balance radial strength with predictable degradation. These technical refinements, coupled with iterative improvements in drug-eluting coatings and delivery systems, are enhancing operator confidence and expanding the clinical scenarios in which resorbable scaffolds are considered viable.

Concurrently, healthcare payment models and hospital procurement strategies are placing greater emphasis on long-term patient outcomes and total cost of care. Value-based care imperatives are prompting health systems to favor devices that demonstrably reduce downstream interventions and rehospitalizations. Regulatory authorities have also clarified expectations for safety and post-market surveillance, which is enabling more efficient pathways to reimbursement and formulary inclusion. In response, manufacturers are prioritizing real-world evidence generation, partnerships with clinical centers of excellence, and lifecycle plans that address post-market data collection and iterative device improvements.

These combined shifts are creating a more competitive environment where clinical differentiation, supply reliability, and robust evidence packages determine the pace and scale of adoption. Organizations that align R&D priorities with payer requirements and clinician needs are positioned to convert technological promise into durable clinical and commercial outcomes.

Cumulative trade policy shifts including United States tariff changes in 2025 prompting supply chain realignment, cost pass-through and strategic sourcing responses

United States tariff actions enacted in 2025 have introduced a new dimension of commercial complexity for companies operating in the biodegradable coronary stents ecosystem, prompting immediate reassessments of procurement, manufacturing, and inventory strategies. Tariff adjustments on raw materials, finished medical devices, or associated components can increase landed costs and compress margins, which in turn influences pricing strategies and contractual negotiations with health systems and distributors. Suppliers and manufacturers are responding by reviewing sourcing footprints, seeking tariff advisory services, and exploring potential tariff mitigation mechanisms available under trade agreements and customs classifications.

The ripple effects extend beyond input costs. Clinical trial supply logistics, capital equipment acquisitions for manufacturing, and cross-border after-sales support are all subject to the operational frictions introduced by tariff regimes. In practice, device makers have accelerated supplier diversification, prioritized local manufacturing or assembly where feasible, and engaged more closely with distributor partners to preserve competitive tendering positions. Purchasers are likewise adapting contracting approaches to include clauses that address tariff-related cost adjustments and to evaluate total landed cost rather than purchase price alone.

Moreover, tariff changes interact with reimbursement and procurement policies, influencing how hospitals and ambulatory centers evaluate vendor bids and long-term device partnerships. Effective responses require coordinated action across regulatory affairs, supply chain, and commercial teams to ensure continuity of supply, transparency in pricing, and alignment with clinician preferences. The net result is a market environment where agility in sourcing and clarity in contractual terms are as important as clinical differentiation.

Segmentation-driven competitiveness highlighting materials selection, clinical indications, care settings and distribution pathways as determinants of adoption and procurement

Segmentation insights reveal how material science, clinical indication, care setting, and distribution pathways collectively shape adoption dynamics for resorbable coronary devices. Material-based differentiation remains foundational: iron-based constructs offer alternative degradation profiles and mechanical behaviors, magnesium-based scaffolds bring a distinct balance of strength and resorption, and polymer platforms-further delineated into PDLLA and PLLA chemistries-present different handling characteristics and drug-elution compatibility. These material choices directly influence procedural workflow, imaging compatibility, and post-procedural monitoring requirements.

Clinical applications bifurcate into patients presenting with acute coronary syndrome and those managed for stable angina, each cohort raising different evidence priorities and risk tolerances. Devices that demonstrate rapid endothelialization and predictably controlled resorption are more likely to be favored in acute settings where thrombosis risk and lesion complexity are heightened, whereas long-term vessel integrity and reduced late complications are paramount considerations in elective stable angina interventions. End-user segmentation further modulates procurement and utilization patterns: ambulatory surgical centers and hospitals display distinct purchasing cycles, inventory management capabilities, and preferences for vendor support. Within ambulatory settings, the contrasts between hospital-owned ambulatory surgical centers and independent facilities affect contracting leverage and logistics, while within hospital systems, cardiac centers and multi-specialty hospitals exhibit different decision-making processes tied to volume, specialty focus, and capital planning.

Distribution channels also play a pivotal role: direct tender relationships typically support larger institutional contracts and tighter price negotiation, whereas third-party distributors provide broader geographic reach and inventory flexibility for smaller or decentralized buyer groups. Taken together, these segmentation axes inform product positioning, clinical evidence strategies, and commercial models that manufacturers must adopt to effectively address heterogeneous customer needs.

Regional dynamics revealing divergent adoption patterns across the Americas, Europe Middle East and Africa, and Asia-Pacific driven by infrastructure, regulation and reimbursement

Regional dynamics exert powerful influence over the trajectory of biodegradable coronary stent adoption, reflecting differences in healthcare infrastructure, regulatory frameworks, and reimbursement environments. In the Americas, clinician familiarity with interventional cardiology innovations and the structure of hospital networks shape rapid technology transfer, but payer scrutiny and procurement protocols require clear demonstration of clinical and economic value. Across Europe, the Middle East and Africa, divergent regulatory regimes and variable reimbursement pathways create a mosaic of adoption timing, with leading cardiac centers often acting as early adopters and diffusion progressing as national health systems and payers align coverage policies.

Asia-Pacific presents a distinct landscape dominated by manufacturing ecosystems, government-led health initiatives, and rapidly expanding procedural volumes in urban centers. Local production capabilities and negotiated pricing frameworks can accelerate availability, while differences in clinical practice patterns and lesion presentations influence device selection. Transitional phrases such as moreover and consequently highlight how cross-regional partnerships, technology transfer arrangements, and regional clinical trials are shaping localized strategies. Manufacturers seeking global traction must therefore craft differentiated approaches that respect regional regulatory timelines, reimbursement considerations, and the operational realities of supply and distribution within each geography.

Competitive profiles and strategic moves by manufacturers, contract partners and distributors influencing technology diffusion and clinical partnerships across care ecosystems

Competitive dynamics are increasingly defined by the depth of clinical partnerships, the agility of manufacturing and distribution networks, and the robustness of post-market evidence programs. Leading device developers are investing in head-to-head clinical collaborations with academic cardiac centers to demonstrate procedural performance and long-term vessel outcomes, while also expanding contract manufacturing partnerships to ensure capacity and component security. Strategic alliances with distributors and integrated delivery networks enable broader reach into ambulatory surgical centers and multi-hospital systems, while dedicated service models-comprising physician training, procedural proctoring, and after-sales clinical support-bolster uptake among high-volume operators.

Companies that prioritize transparent regulatory engagement and active post-market surveillance are better positioned to address clinician concerns about durability and safety. At the same time, contract terms with health systems emphasize service-level agreements, outcome reporting commitments, and supply continuity guarantees. The competitive field is also seeing differentiated plays in adjacent value propositions such as integrated procedural kits, imaging-matched devices, and evidence-backed training curricula. Collectively, these strategic choices establish barriers to entry and create pathways for scale that prioritize clinical trust, operational reliability, and alignment with system-level performance metrics.

Actionable strategies for industry leaders to strengthen resilience, accelerate clinical adoption, and optimize commercial models amid evolving regulatory and trade environments

Industry leaders should pursue a coordinated set of strategic actions to strengthen resilience, accelerate adoption, and capture clinical mindshare in the biodegradable stent domain. First, prioritize clinical evidence generation that aligns with payer and clinician decision criteria, emphasizing real-world outcomes, safety endpoints, and comparative effectiveness across acute coronary syndrome and stable angina cohorts. Second, develop flexible manufacturing footprints and supplier diversification plans that mitigate tariff and trade risks while preserving cost competitiveness and on-time delivery reliability.

Third, tailor commercial models to the needs of distinct end users by offering differentiated support packages for hospital-owned ambulatory surgical centers, independent facilities, cardiac centers, and multi-specialty hospitals; such customization should encompass inventory solutions, clinician training, and outcome reporting tools. Fourth, refine distribution strategies to balance direct tender opportunities with selective third-party distributor partnerships that provide geographic reach without diluting service standards. Fifth, engage proactively with regional regulatory and reimbursement stakeholders to shorten time-to-formulary and to ensure that post-market surveillance commitments are integrated into lifecycle planning. Finally, embed scenario planning for trade policy shifts into corporate governance processes to enable rapid, cross-functional responses when tariff landscapes change. Together, these measures create a coherent playbook for navigating clinical, commercial, and policy complexity.

Robust research methodology integrating primary clinical stakeholder interviews, supply chain mapping and triangulated secondary intelligence to ensure analytical rigor

This analysis is grounded in a multi-method research methodology designed to ensure analytical rigor and practical relevance. Primary qualitative interviews were conducted with interventional cardiologists, procurement officers, regulatory specialists, and distribution partners to capture first-hand perspectives on clinical performance, purchasing drivers, and operational barriers. These conversations were supplemented by supply chain mapping exercises that traced component sourcing, manufacturing dependencies, and distribution pathways to identify potential points of fragility and opportunities for mitigation.

Secondary intelligence was triangulated from regulatory guidance documents, clinical trial registries, peer-reviewed clinical literature, and publicly available procurement policies to validate themes emerging from primary research. Data synthesis emphasized cross-validation, with iterative feedback loops to refine hypotheses and reconcile divergent viewpoints. Analytical frameworks included scenario analysis for trade policy impacts, segmentation-based prioritization for commercial planning, and capability gap assessments to inform recommended strategic actions. Together, these methods produced a nuanced, action-oriented body of insight tailored for device manufacturers, clinical leaders, and purchasing organizations.

Conclusive synthesis underscoring clinical, commercial and policy priorities that will determine the trajectory of biodegradable coronary stents adoption and innovation

The conclusion synthesizes the core findings and clarifies the immediate implications for stakeholders across the biodegradable coronary stents ecosystem. Technological progress in materials and device design, coupled with tighter regulatory expectations and evolving payment models, is elevating the importance of real-world evidence and supply chain resilience. Tariff developments in 2025 add a pragmatic layer of commercial risk that requires integrated responses from procurement, manufacturing, and commercial teams. Adoption trajectories will be shaped not only by device performance but also by the ability of manufacturers to demonstrate predictable supply, post-market vigilance, and alignment with institutional priorities.

Forward-looking organizations will integrate clinical, operational, and commercial strategies to convert innovation into sustained clinical adoption. This requires disciplined evidence programs, flexible sourcing and manufacturing arrangements, and commercial offerings tailored to the needs of different care settings and regional markets. Ultimately, the successful diffusion of biodegradable coronary stents will depend on how well stakeholders manage the intersection of clinical value, operational execution, and policy-driven commercial constraints.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biodegradable Coronary Stents Market, by Material

  • 8.1. Iron
  • 8.2. Magnesium
  • 8.3. Polymer
    • 8.3.1. Pdlla
    • 8.3.2. Plla

9. Biodegradable Coronary Stents Market, by Application

  • 9.1. Acute Coronary Syndrome
  • 9.2. Stable Angina

10. Biodegradable Coronary Stents Market, by End User

  • 10.1. Ambulatory Surgical Centers
    • 10.1.1. Hospital-Owned Ambulatory Surgical Centers
    • 10.1.2. Independent Ambulatory Surgical Centers
  • 10.2. Hospitals
    • 10.2.1. Cardiac Centers
    • 10.2.2. Multi-Specialty Hospitals

11. Biodegradable Coronary Stents Market, by Distribution Channel

  • 11.1. Direct Tender
  • 11.2. Third Party Distributor

12. Biodegradable Coronary Stents Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Biodegradable Coronary Stents Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Biodegradable Coronary Stents Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Biodegradable Coronary Stents Market

16. China Biodegradable Coronary Stents Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Amaran Biotechnology Co., Ltd.
  • 17.7. Amendia, Inc.
  • 17.8. Arterial Remodeling Technologies, Inc.
  • 17.9. Biomedical Structures, Inc.
  • 17.10. Biotronik SE & Co. KG
  • 17.11. Boston Scientific Corporation
  • 17.12. Cook Medical LLC
  • 17.13. Cordis Corporation
  • 17.14. Elixir Medical Corporation
  • 17.15. Endologix, Inc.
  • 17.16. HeartFlow, Inc.
  • 17.17. Hengrui Medicine Co., Ltd.
  • 17.18. Inflow Dynamics Corp.
  • 17.19. Johnson & Johnson Services, Inc.
  • 17.20. Lepu Medical Technology (Beijing) Co., Ltd.
  • 17.21. Meril Life Sciences Pvt. Ltd.
  • 17.22. OrbusNeich Medical Company
  • 17.23. Reva Medical, Inc.
  • 17.24. Shanghai MicroPort Medical (Group) Co., Ltd.
  • 17.25. Sino Medical Sciences Technology Inc.
  • 17.26. Svelte Medical Systems Ltd.
  • 17.27. Terumo Corporation
  • 17.28. Translumina GmbH
  • 17.29. Xeltis AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES BIODEGRADABLE CORONARY STENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA BIODEGRADABLE CORONARY STENTS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY IRON, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY IRON, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY IRON, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY MAGNESIUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY MAGNESIUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY MAGNESIUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY POLYMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY POLYMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY POLYMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY PDLLA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY PDLLA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY PDLLA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY PLLA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY PLLA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY PLLA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY STABLE ANGINA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY STABLE ANGINA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY STABLE ANGINA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY HOSPITAL-OWNED AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY HOSPITAL-OWNED AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY HOSPITAL-OWNED AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY INDEPENDENT AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY INDEPENDENT AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY INDEPENDENT AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY CARDIAC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY CARDIAC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY CARDIAC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY MULTI-SPECIALTY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY MULTI-SPECIALTY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY MULTI-SPECIALTY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY DIRECT TENDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY DIRECT TENDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY DIRECT TENDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY THIRD PARTY DISTRIBUTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY THIRD PARTY DISTRIBUTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY THIRD PARTY DISTRIBUTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. GCC BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GCC BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 130. GCC BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 131. GCC BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. GCC BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. GCC BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 134. GCC BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 135. GCC BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. G7 BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. G7 BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 154. G7 BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 155. G7 BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. G7 BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. G7 BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 158. G7 BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 159. G7 BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. NATO BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. NATO BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 162. NATO BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 163. NATO BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. NATO BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. NATO BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 166. NATO BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 167. NATO BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES BIODEGRADABLE CORONARY STENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED STATES BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED STATES BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED STATES BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. CHINA BIODEGRADABLE CORONARY STENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 178. CHINA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 180. CHINA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. CHINA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. CHINA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 183. CHINA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA BIODEGRADABLE CORONARY STENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)